The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Open accessAbstract
Mesothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an attractive target for cancer immunotherapy because its normal expression is limited to mesothelial cells, which are dispensable. Several antibody-based therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing clinical evaluation. These include antimesothelin immunotoxins (SS1P, RG7787/LMB-100), chimeric antimesothelin antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab ravtansine, DMOT4039A, BMS-986148), live attenuated Listeria monocytogenes–expressing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen receptor T-cell therapies. Two antimesothelin agents are currently in multicenter clinical registration trials for malignant mesothelioma: amatuximab in the first-line setting and anetumab ravtansine as second-line therapy. Phase II randomized clinical trials of CRS-207 as a boosting agent and in combination with immune checkpoint inhibition for pancreatic cancer are nearing completion. These ongoing studies will define the utility of mesothelin immunotherapy for treating cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Chang, K., & Pastan, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 745
Self-citationLe, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Self-citationJaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.145 · Cited by 600
Self-citationArgani, P., Iacobuzio–Donahue, C. A., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E. M., Yeo, C. J., et al. (2001) · PubMed · Cited by 574
Self-citationBinding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
Self-citationMesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 477
Gubbels, J. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T. K., Connor, J., Sathyanarayana, B. K., Lee, B., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-50 · Cited by 422
Self-citationApplication of Mesothelin Immunostaining in Tumor Diagnosis
Ordóñez, N. G. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200311000-00003 · Cited by 382
Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., & Pastan, I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0869 · Cited by 379
Self-citationLe, D. T., Brockstedt, D. G., Nir-Paz, R., Hampl, J., Mathur, S., Nemunaitis, J., Sterman, D. H., Hassan, R., Lutz, E., Moyer, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2121 · Cited by 369
Self-citationThomas, A. M., Santarsiero, L. M., Lutz, E. R., Armstrong, T. D., Chen, Y.-C., Huang, L.-Q., Laheru, D. A., Goggins, M., Hruban, R. H., & Jaffee, E. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031435 · Cited by 347
Self-citationFrequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma.
Sato, N., Maitra, A., Fukushima, N., van Heek, N. T., Matsubayashi, H., Iacobuzio–Donahue, C. A., Rosty, C., & Goggins, M. (2003) · PubMed · Cited by 304
Listeria-based cancer vaccines that segregate immunogenicity from toxicity
Brockstedt, D. G., Giedlin, M. A., Leong, M. L., Bahjat, K. S., Gao, Y., Luckett, W., Liu, W., Cook, D. N., Portnoy, D. A., & Dubensky, T. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406035101 · Cited by 299
Chang, K., Pastan, I., & Willingham, M. C. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500308 · Cited by 271
Self-citationValue of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
Ordóñez, N. G. (2003) · Modern Pathology · doi:10.1097/01.mp.0000056981.16578.c3 · Cited by 259
Improving antibody affinity by mimicking somatic hypermutation in vitro
Chowdhury, P. S., & Pastan, I. (1999) · Nature Biotechnology · doi:10.1038/9872 · Cited by 256
Self-citationMesothelin Is Not Required for Normal Mouse Development or Reproduction
Bera, T. K., & Pastan, I. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2902-2906.2000 · Cited by 253
Self-citationDiscovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Pastan, I., & Hassan, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0337 · Cited by 252
Self-citationGolfier, S., Kopitz, C., Kahnert, A., Heisler, I., Schatz, C. A., Stelte-Ludwig, B., Mayer-Bartschmid, A., Unterschemmann, K., Bruder, S., Linden, L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0926 · Cited by 249
Hassan, R., Laszik, Z. G., Lerner, M., Raffeld, M., Postier, R., & Brackett, D. (2005) · American Journal of Clinical Pathology · doi:10.1309/f1b6-4cl7-h8vj-keaf · Cited by 236
Self-citationHassan, R., Miller, A. C., Sharon, E., Thomas, A., Reynolds, J. C., Ling, A., Kreitman, R. J., Miettinen, M. M., Steinberg, S. M., Fowler, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006941 · Cited by 234
Self-citationChen, S.-H., Hung, W.-C., Wang, P., Paul, C., & Konstantopoulos, K. (2013) · Scientific Reports · doi:10.1038/srep01870 · Cited by 231
Chowdhury, P. S., Viner, J. L., Beers, R., & Pastan, I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.669 · Cited by 222
Self-citationPhase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Kreitman, R. J., Hassan, R., FitzGerald, D. J., & Pastan, I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0062 · Cited by 222
Self-citationServais, E. L., Colovos, C., Rodriguez, L., Bograd, A. J., Nitadori, J.-I., Sima, C., Rusch, V. W., Sadelain, M., & Adusumilli, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2614 · Cited by 202
Hassan, R., Cohen, S. J., Phillips, M., Pastan, I., Sharon, E., Kelly, R. J., Schweizer, C., Weil, S., & Laheru, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2275 · Cited by 201
Self-citationPreclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan, R., Ebel, W., Routhier, E., Patel, R. K., Kline, J. B., Zhang, J., Chao, Q., Jacob, S. M., Turchin, H. A., Gibbs, L. S., et al. (2007) · PubMed · Cited by 186
Self-citationKachala, S. S., Bograd, A. J., Villena-Vargas, J., Suzuki, K., Servais, E. L., Kadota, K., Chou, J., Sima, C. S., Vertes, E., Rusch, V. W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1862 · Cited by 185
Hassan, R., Kindler, H. L., Jahan, T., Bazhenova, L., Reck, M., Thomas, A., Pastan, I., Parno, J., O'Shannessy, D. J., Fatato, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0804 · Cited by 180
Self-citationLocalization of Mesothelin in Epithelial Ovarian Cancer
Hassan, R., Kreitman, R. J., Pastan, I., & Willingham, M. C. (2005) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/01.pai.00000141545.36485.d6 · Cited by 178
Self-citationMesothelin, a novel immunotherapy target for triple negative breast cancer
Tchou, J., Wang, L.-C., Selven, B., Zhang, H., Conejo-Garcia, J., Borghaei, H., Kalos, M., Vondeheide, R. H., Albelda, S. M., June, C. H., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2018-4 · Cited by 172
Frierson, H. F., Moskaluk, C. A., Powell, S. M., Zhang, H., Cerilli, L. A., Stoler, M. H., Cathro, H., & Hampton, G. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00177-1 · Cited by 171
High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
Cheng, W.-F., Huang, C.-Y., Chang, M.-C., Hu, Y.-H., Chiang, Y.-C., Chen, Y.-L., Hsieh, C.-Y., & Chen, C.-A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604964 · Cited by 170
Hassan, R., Sharon, E., Thomas, A., Zhang, J., Ling, A., Miettinen, M., Kreitman, R. J., Steinberg, S. M., Hollevoet, K., & Pastan, I. (2014) · Cancer · doi:10.1002/cncr.28875 · Cited by 168
Self-citationMesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways
Chang, M.-C., Chen, C.-A., Chen, P.-J., Chiang, Y.-C., Chen, Y.-L., Mao, T.-L., Lin, H.-W., Lin Chiang, W.-H., & Cheng, W.-F. (2012) · Biochemical Journal · doi:10.1042/bj20110282 · Cited by 165
Liu, W., Onda, M., Lee, B., Kreitman, R. J., Hassan, R., Xiang, L., & Pastan, I. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209292109 · Cited by 160
Self-citationMesothelin Expression in Human Lung Cancer
Ho, M., Bera, T. K., Willingham, M. C., Onda, M., Hassan, R., FitzGerald, D., & Pastan, I. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2161 · Cited by 156
Self-citationBharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-106 · Cited by 151
Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays
Swierczynski, S. L., Maitra, A., Abraham, S. C., Iacobuzio–Donahue, C. A., Ashfaq, R., Cameron, J. L., Schulick, R. D., Yeo, C. J., Rahman, A., Hinkle, D. A., et al. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.10.012 · Cited by 144
Winter, J. M., Tang, L. H., Klimstra, D. S., Brennan, M. F., Brody, J. R., Rocha, F. G., Jia, X., Qin, L., D'Angelica, M. I., DeMatteo, R. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040157 · Cited by 123
Weekes, C. D., Lamberts, L. E., Borad, M. J., Voortman, J., McWilliams, R. R., Diamond, J. R., de Vries, E. G. E., Verheul, H. M. W., Lieu, C. H., Kim, G. P., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0693 · Cited by 119
Bharadwaj, U., Marin-Muller, C., Li, M., Chen, C., & Yao, Q. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr075 · Cited by 118
Tozbikian, G. H., Brogi, E., Kadota, K., Catalano, J. P., Akram, M. M., Patil, S. N., Ho, A. Y., Reis-Filho, J. S., Weigelt, B., Norton, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114900 · Cited by 116
Shimizu, A., Hirono, S., Tani, M., Kawai, M., Okada, K., Miyazawa, M., Kitahata, Y., Nakamura, Y., Noda, T., Yokoyama, S., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02214.x · Cited by 114
Uehara, N., Matsuoka, Y., & Tsubura, A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0254 · Cited by 107
Sathyanarayana, B. K., Hahn, Y., Patankar, M. S., Pastan, I. H., & Lee, B. (2009) · BMC Structural Biology · doi:10.1186/1472-6807-9-1 · Cited by 106
Self-citationHollevoet, K., Mason‐Osann, E., Liu, X., Imhof-Jung, S., Niederfellner, G. J., & Pastan, I. H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0089-t · Cited by 103
Self-citationDiffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma
Yen, M. J., Hsu, C.-Y., Mao, T., Wu, T. ‐., Roden, R. B. S., Wang, T., & Shih, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1397 · Cited by 101
Lamberts, L. E., van Oordt, C. W. M. D. H., ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., Hoekstra, O. S., Williams, S. P., Fine, B. M., Maslyar, D. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1272 · Cited by 100
Mesothelin as a Target for Chimeric Antigen Receptor-Modified T Cells as Anticancer Therapy
O’Hara, M. H., Stashwick, C., Haas, A. R., & Tanyi, J. L. (2016) · Immunotherapy · doi:10.2217/imt.16.4 · Cited by 90
Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
Einama, T., Homma, S., Kamachi, H., Kawamata, F., Takahashi, K., Takahashi, N., Taniguchi, M., Kamiyama, T., Furukawa, H., Matsuno, Y., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.235 · Cited by 88
Thomas, A., Chen, Y., Steinberg, S. M., Luo, J., Pack, S., Raffeld, M. A., Abdullaev, Z., Alewine, C., Rajan, A., Giaccone, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3429 · Cited by 86
Self-citationMarín‐Müller, C., Li, D., Bharadwaj, U., Li, M., Chen, C., Hodges, S. E., Fisher, W. E., Mo, Q., Hung, M., & Yao, Q. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3776 · Cited by 85
Hucl, T., Brody, J. R., Gallmeier, E., Iacobuzio–Donahue, C. A., Farrance, I. K. G., & Kern, S. E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0474 · Cited by 76
Scales, S. J., Gupta, N., Pacheco, G., Firestein, R., French, D. M., Koeppen, H., Rangell, L. K., Barry-Hamilton, V., Luis, E., Chuh, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0487-t · Cited by 64
Mesothelin expression correlates with prolonged patient survival in gastric cancer
Baba, K., Ishigami, S., Arigami, T., et al. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22024 · Cited by 63
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer
Kawamata, F., Kamachi, H., Einama, T., Homma, S., Tahara, M., MIYAZAKI, M., Tanaka, S., Kamiyama, T., Nishihara, H., Taketomi, A., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1662 · Cited by 61
Mesothelin expression is associated with poor outcomes in breast cancer
Li, Y. R., Xian, R. R., Ziober, A. F., Conejo-Garcia, J. R., Perales‐Puchalt, A., June, C. H., Zhang, P. J., & Tchou, J. C. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3077-5 · Cited by 58
Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding
Zhang, Y., Chertov, O., Zhang, J., Hassan, R., & Pastan, I. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0466 · Cited by 54
Self-citationNew Life for Immunotoxin Cancer Therapy
Hassan, R., Alewine, C., & Pastan, I. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1623 · Cited by 52
Self-citationLindenberg, L., Thomas, A., Adler, S., Mena, E., Kurdziel, K., Maltzman, J. D., Wallin, B., Hoffman, K., Pastan, I. H., Paik, C. H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2883 · Cited by 47
Self-citationMesothelin Expression Is a Prognostic Factor in Cholangiocellular Carcinoma
Nomura, R., Fujii, H., Abe, M., Sugo, H., Ishizaki, Y., Kawasaki, S., & Hino, O. (2013) · International Surgery · doi:10.9738/intsurg-d-13-00001.1 · Cited by 44
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).
Blumenschein, G. R., Hassan, R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Rajagopalan, P., Walter, A. O., Sarapa, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2509 · Cited by 37
Self-citationTan, K., Kajino, K., Momose, S., Masaoka, A., Sasahara, K., Shiomi, K., Izumi, H., Abe, M., Ohtsuji, N., Wang, T., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.03.002 · Cited by 35
Ren, Y. R., Patel, K. G., Paun, B. C., & Kern, S. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193458 · Cited by 33
Alvarez, H., Rojas, P. L., Yong, K., Ding, H. Y., Xu, G., Prasad, P. N., Wang, J. C. Y., Canto, M. I., Eshleman, J. R., Montgomery, E. A., et al. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.06.006 · Cited by 22
Galloway, M. L., Murray, D., & Moffat, D. (2006) · Histopathology · doi:10.1111/j.1365-2559.2005.02279.x · Cited by 22
Gupta, A., Hussein, Z., Hassan, R., Wustner, J., Maltzman, J. D., & Wallin, B. A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2984-z · Cited by 18
Self-citation
Cited by
Huang, H., Wang, Z., Zhang, Y., Pradhan, R. N., Ganguly, D., Chandra, R., Murimwa, G., Wright, S., Gu, X., Maddipati, R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.011 · Cited by 542
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Clinical Significance of Histologic Subtyping of Malignant Pleural Mesothelioma
Brcic, L., & Kern, I. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.38 · Cited by 77
Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies
Zhan, J., Lin, D., Watson, N., Esser, L., Tang, W. K., Zhang, A., Liu, X., Hassan, R., Gleinich, A., Shajahan, A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0306 · Cited by 28
Self-citation
Metadata
- Authors
- Hassan, R., Thomas, A., Alewine, C., Le, D. T., Jaffee, E. M., & Pastan, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-12-01
- Volume
- 34
- Issue
- 34
- Pages
- 4171-4179
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2531335004
- Cited by
- 325
- References
- 71
- FWCI
- 16.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.